Syndax's menin inhibitor succeeds in pivotal trial, but investors aren't impressed

Syndax Pharmaceuticals said its experimental menin inhibitor met the primary endpoint in a pivotal trial for certain leukemia patients, and it's planning a regulatory filing in the first half of 2025. But investors were underwhelmed ...